RESUMEN

The pharmacokinetics of lipid-bound and liberated amphotericin B (AMB) was assessed in 11 critically ill patients with cholestatic liver disease (CSLD) and in 9 subjects with normal liver function treated with AMB colloidal dispersion (ABCD). Exposure to lipid-bound AMB was higher in patients with CSLD. Levels of liberated AMB were elevated by CSLD only after the first dose, whereas its pharmacokinetics was unaffected at steady state. The standard dosage of ABCD is probably adequate for patients with CSLD.

Asunto(s)

Anfotericina B/farmacocinética , Antifúngicos/farmacocinética , Enfermedad Crítica , Hepatopatías/sangre , Adolescente , Adulto , Anciano , Anfotericina B/sangre , Antifúngicos/sangre , Niño , Coloides , Femenino , Humanos , Hepatopatías/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Adulto Joven